IHMCSA: International Human Microbiome Coordination and Support Action
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Humans are microbial, living in close functional interaction with their skin and mucosal microbiomes. Human-microbes interplay has proven es...
2021-01-22 - 2024-04-30 | Financiado
2021-01-22 - 2024-04-30 | Financiado
A-TANGO: NOVEL TREATMENT OF ACUTE ON CHRONIC LIVER FAILURE USING SYNERGISTIC ACTION OF G CSF AND TAK 242
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
tramitó un
H2020:
H2020-SC1-BHC-2018-2020
In Europe, about 30,000 people die every year from alcohol related cirrhosis, a form of chronic, non- communicable disease. The patients tha...
2021-01-18 - 2026-02-28 | Financiado
2021-01-18 - 2026-02-28 | Financiado
DECISION: DECOMPENSATED CIRRHOSIS IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
tramitó un
H2020:
H2020-SC1-BHC-2018-2020
In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. developm...
2019-12-05 - 2025-09-30 | Financiado
2019-12-05 - 2025-09-30 | Financiado
MICROB-PREDICT: MICROBiome based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
tramitó un
H2020:
H2020-SC1-BHC-2018-2020
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome i...
2018-12-03 - 2025-03-31 | Financiado
2018-12-03 - 2025-03-31 | Financiado
LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
participó en un
H2020:
H2020-SC1-2016-2017
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | Financiado
2016-12-09 - 2023-02-28 | Financiado
ALIVER: Development of DIALIVE a novel Liver Dialysis Device for the treatment of patients with Acute on Ch...
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
participó en un
H2020:
H2020-SC1-2016-2017
Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe. In liver failure, the accumulation...
2016-12-01 - 2021-01-31 | Financiado
2016-12-01 - 2021-01-31 | Financiado
CARBALIVE: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of live...
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
participó en un
H2020:
H2020-PHC-2014-2015
Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-c...
2015-04-07 - 2021-01-31 | Financiado
2015-04-07 - 2021-01-31 | Financiado
* No se disponen de datos de la empresa actual.